Overview

The global Botulinum Toxin Market is assessed to value over US$ 8 billion by the end of 2027 and grow at a CAGR of over 7% during the forecast period of 2020-2027.

Injecting Botulinum toxin type A (BOTOX) into the affected muscles has been an effective method for treating hardened tissues preventing its damage. Basically, muscles that are responsible for gnathological-related diseases are restored. BOTOX is a natural protein produced by Clostridium botulinum, which is an anaerobic bacterium. It initiates the release of acetylcholine (ACH), which is a neurotransmitter responsible for activating glandular secretions and muscle contraction and administrating it results in tone reduction of the targeted muscle. This toxin A has several clinical applications includes Prophylaxis of headaches in adult patients with chronic migraine, bruxism, rhinitis, sialorrhea, crocodile tears (lacrimation), pain (most commonly neuralgic origin), hyperhidrosis, foot dystonia, axial dystonia, Writer's cramp (WC) and other occupational cramps.

Botulinum Toxin Market Overview

Clinically botulinum is used for the treatment of strabismus and huge demand in cosmetic applications. Growing research activities expanded the scope of botulinum for the treatment of neurological conditions like spasticity, dystonia, tremor, and others. Along with this, recent research activities have concluded that botulinum is also used for autonomic disorders like hypersecretory disorders, detrusor sphincter, and others. The growing demand of botulinum in disease management led to the robust growth of the market. Further, the increasing importance of botulinum in chemo-denervation and dermal filling created huge demand among the general population. Along with this, the growing importance of aesthetics and personal appearance among the general population led to the robust growth of the market. All these factors led to the burgeoning growth of the market.

High spending capacity and huge demand aesthetics among the general population of developed economies fuelled the growth of the global market. Developed economies like North America and Europe account for more 60% of the market share. The US dominated the North America market due to high penetration among the general population and end-user segment. UK, Germany, France, and Italy dominated the European market. The Asia Pacific is the most opportunistic market space for market players due to the limited presence of manufacturers. It represented a fast-growing region during the forecast period. Latin America and Rest of World is a highly untapped market due to the limited presence of manufacturers and less adoption.

Major players included in the Botulinum Toxin Market:
• Allergan
• Merz Pharma
• Medytox
• Galderma
• Lanzhou Institute of Biological Products Co.,Ltd
• Hugel,Inc
• Revanance Therapeutics,Inc
• US WorldMeds,LLC
• Ipsen group
• Eisai Co., Ltd
• Evolus, Inc
• AbbVie
• Pfizer Inc
(Note: The list of the major players will be updated with the latest market scenario and trends)

Botulinum Toxin Market Segmentation:

By Application
• Therapeutic
   o Chronic Migraine
   o Spasticity
   o Overactive Bladder
   o Cervical Dystonia
   o Blepharospasm
   o Others
• Aesthetic

By Type 
• Botulinum Toxin A
• Botulinum Toxin B

By End-User 
• Specialty & Dermatology Clinics
• Hospitals & Clinics
Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Botulinum Toxin Market By Application, By Type, By End-User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Application launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1 Objectives of the Study 
   1.2 Market Definition 
   1.3 Market Scope 
       1.3.1 Years Considered for the Study
       1.3.2 Market Covered
   1.4 Currency 
   1.5 Limitations 
   1.6 Stakeholders 

2. Research Methodology 
    2.1 Research Data 
        2.1.1 Secondary Data
              2.1.1.1 Key Data from Secondary Sources
        2.1.2 Primary Data
              2.1.2.1 Key Data from Primary Sources
    2.2 Market Size Estimation 
    2.3 Market Breakdown and Data Triangulation 
    2.4 Assumptions for the Study  

3. Executive Summary
   3.1 Market Outlook
   3.2 Segment Outlook
   3.3 Competitive Insights

4. Global Botulinum Toxin Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Botulinum Toxin Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Botulinum Toxin Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Botulinum Toxin Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
   7.1. Therapeutic
        7.1.1. Chronic Migraine
        7.1.2. Spasticity
    7.1.3. Overactive Bladder
    7.1.4. Cervical Dystonia
    7.1.5. Blepharospasm
    7.1.6. Others
   7.2. Aesthetic

8. Global Botulinum Toxin Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)  
   8.1. Botulinum Toxin A
   8.2. Botulinum Toxin B

9. Global Botulinum Toxin Market, By End-User Historical Analysis and Forecast 2020-2027 (USD Million)  
   9.1. Specialty & Dermatology Clinics
   9.2. Hospitals & Clinics
   9.3. Others

10. North America Botulinum Toxin Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
        10.2.1. U.S.A
        10.2.2. Canada
        10.2.3. Mexico
   10.3. Market Size (USD Million) Forecast for North America 2020-2027

11. Latin America Botulinum Toxin Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2020-2027

12. Europe Botulinum Toxin Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2020-2027

13. Asia Pacific Botulinum Toxin Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          14.2.1. Saudi Arabia
          14.2.2. UAE
          14.2.3. South Africa
          14.2.4. Egypt
    14.3. Market Size (USD Million) Forecast for MEA 2020-2027

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4.  North America - Market Share Analysis and Key Regional Players
    15.5.  Europe - Market Share Analysis and Key Regional Players
    15.6.  Asia Pacific - Market Share Analysis and Key Regional Players
    15.7.  Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Applications Offered and Financial Layouts)
    16.1. Allergan
          16.1.1. Company Overview
          16.1.2. Application Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Merz Pharma
          16.2.1. Company Overview
          16.2.2. Application Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Medytox
          16.3.1. Company Overview
          16.3.2. Application Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Galderma
          16.4.1. Company Overview
          16.4.2. Application Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Lanzhou Institute of Biological Products Co.,Ltd
          16.5.1. Company Overview
          16.5.2. Application Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Hugel,Inc
          16.6.1. Company Overview
          16.6.2. Application Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview      
    16.7. Revanance Therapeutics,Inc
          16.7.1. Company Overview
          16.7.2. Application Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. US WorldMeds,LLC
          16.8.1. Company Overview
          16.8.2. Application Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Ipsen group
          16.9.1. Company Overview
          16.9.2. Application Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview 
    16.10.Eisai Co., Ltd,
          16.10.1. Company Overview
          16.10.2. Application Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview 
    16.11.Evolus, Inc
          16.11.1. Company Overview
          16.11.2. Application Portfolio
          16.11.3. SWOT Analysis
          16.11.4. Financial Overview
          16.11.5. Strategic Overview 
    16.12.AbbVie
          16.12.1. Company Overview
          16.12.2. Application Portfolio
          16.12.3. SWOT Analysis
          16.12.4. Financial Overview
          16.12.5. Strategic Overview 
    16.13.Pfizer Inc
          16.13.1. Company Overview
          16.13.2. Application Portfolio
          16.13.3. SWOT Analysis
          16.13.4. Financial Overview
          16.13.5. Strategic Overview 

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client
 

Tables

Figures